Colon Cancer Clinical Trial
Official title:
A Multicenter Randomized Clinical Trial Comparing Intracorporeal and Extracorporeal Ileocolic Anastomotic After Laparoscopic Right Colectomy for Colon Cancer (COLOR IV)
Background: Laparoscopic assisted right hemicolectomy is recommended for right colon cancer. As a more minimally invasive procedure, intracorporeal ileocolic anastomosis has potential advantages: reducing torsion and traction on the mesentery, reducing skin incision length and enhancing postoperative recovery. However, the longer operative time, greater risk of intra-abdominal infection and steep learning curve for intestinal anastomosis performed under laparoscopic conditions, does this increase the incidence of postoperative complications, especially the incidence of anastomotic leakage, and whether it affects There is no high-level research evidence on the survival of patients. Study design: COlOR IV study is an international prospective, multicenter, randomized controlled clinical study of intraperitoneal anastomosis versus extraperitoneal anastomosis after laparoscopic right hemicolectomy for colon cancer . The study will include a quality assessment phase before randomisation to ensure required competency level and uniformity of the intracorporeal and extracoporeal techniques. Endpoint: Primary outcome is anastomotic leakage within 30 days after surgery. Main secondary endpoint is 3-year disease-free survival rate. Secondary endpoints are mortality and morbidity, postoperative recovery, overall survival, surgical specimen quality, quality of life. Statistics: The primary endpoint is anastomotic leakage within 30 days after surgery. The anastomotic leakage rate was set to 2% in the both groups, and an increase in the incidence of anastomotic leakage of 2.5% was considered inferior. The one-sided significance level was 0.025, the power was 0.9. The dropout rate was 20%, and taking into account the post-randomization analysis (dropout 5%), the total sample size was 1158. There were 579 cases in the intracorporeal anastomosis group and 579 cases in the extracorporeal anastomosis group. Main selection: Patients with histologically proven right colon cancer (cecum, ascending colon and proximal 1/3 of the transverse colon malignant tumor), clinically stage I-III, and intention for right hemicolectomy with primary anastomosis. Hypothesis: The hypothesis is that intracoporeal anastomosis will have comparable anastomotic leak rate and 3-year DFS, but faster postoperative recovery with extracoporeal anastomosis.
Status | Not yet recruiting |
Enrollment | 1158 |
Est. completion date | January 1, 2030 |
Est. primary completion date | January 1, 2027 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 80 Years |
Eligibility | Inclusion criteria 1. Age: 18 ~ 80 years, male or female; 2. Histological or cytological diagnosis of right colon cancer (cecum, ascending colon and proximal 1/3 of the transverse colon cancer); 3. Stage I-III according to the AJCC-TNM classification including downstaged tumor based on adequate imaging of the thorax and abdomen; 4. Intention for right hemicolectomy (including extended right hemicolectomy) with primary anastomosis; 5. Informed consent according to local requirements Exclusion criteria 1) T4b tumor determined by CT scan; 2) Malignancy other than adenocarcinoma at histological examination ; 3)Other malignancies in medical history, except adequately treated basocellular carcinoma of the skin or in situ carcinoma of the cervix uteri; 4) Previous history of colorectal cancer or synchronous multiple colorectal malignancies; 5) Complications requiring emergency surgery (obstruction, perforation, etc); 6) Planned synchronous abdominal organ resections; 7) Pregnant or lactating women; 8) Familial Adenomatosis Polyposis Coli (FAP), active Crohn's disease or active ulcerative colitis; 9) Absolute contraindication to general anesthesia or laparoscopic surgery. |
Country | Name | City | State |
---|---|---|---|
n/a |
Lead Sponsor | Collaborator |
---|---|
Beijing Friendship Hospital |
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Anastomotic leak | Anastomotic leakage is defined as a defect of the intestinal wall at the anastomotic site leading to a communication between intra- and extraluminal compartments.
Diagnosis of anastomotic leakage: The radiological examination (CT abdomen) will be completed if clinically suspected AL. AL is confirmed clinically, radiologically, endoscopically or intraoperatively. The severity of anastomotic leakage was judged with reference to the Clavien-Dindo classification. |
30 days | |
Secondary | Disease-free survival rate | Main secondary outcome | 3/5 years | |
Secondary | Overall survival | 3/5 years | ||
Secondary | morbidity | 5 years | ||
Secondary | Mortality | 5 years | ||
Secondary | Duration of surgery | from incision to suture completion | Intraoperative | |
Secondary | Duration of anastomosis | from the start of dissection of the bowel to the compeletion of the anastomosis | Intraoperative | |
Secondary | Surgical incision length | Intraoperative | ||
Secondary | Conversion rate | conversion to open surgery or conversion to extracorporeal anastomosis | 1 month | |
Secondary | Pain score (VAS score) | The Visual Analogue Scale (VAS) measures pain intensity. The VAS consists of a 10cm line, with two end points representing 0 ('no pain') and 10 ('pain as bad as it could possibly be'). Ask the patient to rate their current level of pain by placing a mark on the line. | 1-3 days | |
Secondary | Time to first flatus passage after surgery | The day of surgery is day 0. The time interval between the day of the first flatus passage after surgery and the day of surgery. | 1 month | |
Secondary | Time to first stool passage after surgery | The day of surgery is day 0. The time interval between the day of the first stool passage after surgery and the day of surgery. | up to 1 week | |
Secondary | Time to first oral intake | The day of surgery is day 0. The time interval between the day of the first oral intake after surgery and the day of surgery. | up to 1 week | |
Secondary | Length of hospital stay after surgery | days from surgery to discharge | 1 month | |
Secondary | Specimen quality | West pathological assessment criteria. Grading of the plane of mesocolic dissection.
Muscularis propria plane:little bulk to mesocolon with disruptions extending down onto the muscularis propriapropria Intramesocolic plane: moderate bulk to mesocolon with irregularity but the incisions do not reach down to the muscularis propria Mesocolic plane: intact mesocolon with a smooth peritoneal-lined surface |
1 month | |
Secondary | Health-related quality of life | EORTC QLQ-CR29 and C30: questionnaires to evaluate the overall quality of life of patients with colorectal cancer, including 30 and 29 items, respectively, to score patients' overall quality of life, function, and symptoms. These are coded with four-point scales, namely "Not at all", "A little", "Quite a bit" and "Very much." | 1 year | |
Secondary | health-related quality of life | EQ 5D-5L (Euroqol): This questionnaire is a simple, generic tool for describing and assessing health-related quality of life. It consists of 5 items (mobility, personal care, activities of daily living, pain and anxiety and depression) that answer questions on a 5-point scale ranging from "no problem" (level 1) to "very severe" (level 5). | 1 year | |
Secondary | Incision herniation | The incision herniation is classified by the criteria of the European Hernia Society. The location (Midline/Lateral) and size (length and width) of the herniation will be recorded. | 1 year |
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT05551052 -
CRC Detection Reliable Assessment With Blood
|
||
Completed |
NCT03457454 -
Reducing Rural Colon Cancer Disparities
|
||
Recruiting |
NCT06006390 -
CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT04088955 -
A Digimed Oncology PharmacoTherapy Registry
|
||
Recruiting |
NCT06010862 -
Clinical Study of CEA-targeted CAR-T Therapy for CEA-positive Advanced/Metastatic Malignant Solid Tumors
|
Phase 1 | |
Terminated |
NCT01347645 -
Irinotecan Plus E7820 Versus FOLFIRI in Second-Line Therapy in Patients With Locally Advanced or Metastatic Colon or Rectal Cancer
|
Phase 1/Phase 2 | |
Completed |
NCT03390907 -
Hybrid APC Assisted EMR for Large Colon Polyps
|
N/A | |
Recruiting |
NCT03175224 -
APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors
|
Phase 2 | |
Completed |
NCT04079478 -
The AID Study: Artificial Intelligence for Colorectal Adenoma Detection
|
||
Active, not recruiting |
NCT04057274 -
Acute Effect of modeRate-intensity aerOBIc Exercise on Colon Cancer Cell Growth
|
N/A | |
Recruiting |
NCT03190941 -
Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing the G12V Variant of Mutated RAS in HLA-A*11:01 Patients
|
Phase 1/Phase 2 | |
Not yet recruiting |
NCT05147545 -
Impact of Exercise and Hyperlipidic Meal on Free Circulating DNA in Patients With Metastatic Colonic Cancer and Healthy Subjects
|
N/A | |
Recruiting |
NCT05026268 -
The Laparoscopic Right Colectomy With Intracoroporeal Anastomosis
|
N/A | |
Not yet recruiting |
NCT03277235 -
Effect of a Resilience Model-Based Care Plan in Newly Diagnosed Colorectal Cancer Patients
|
N/A | |
Active, not recruiting |
NCT02730702 -
Colon Cancer Risk-stratification Via Optical Analysis of Rectal Ultrastructure
|
||
Active, not recruiting |
NCT02959541 -
PK/PD Investigation of Calciumfolinat in Blood, Tumor and Adjacent Mucosa in Patient With Colon Cancer
|
N/A | |
Completed |
NCT02810652 -
Perioperative Geriatrics Intervention for Older Cancer Patients Undergoing Surgical Resection
|
N/A | |
Recruiting |
NCT02577627 -
Multi-Indication, Retrospective Oncological Study to Validate the Accuracy in Predicting TTP by PrediCare in Patients Under SOC
|
N/A | |
Terminated |
NCT02628535 -
Safety Study of MGD009 in B7-H3-expressing Tumors
|
Phase 1 | |
Recruiting |
NCT02526836 -
Complete Mesocolic Excision With Central Vessel Ligation Compared With Conventional Surgery for Colon Cancer
|
Phase 2/Phase 3 |